Role of neuroendocrine and neuroimmune mechanisms in chronic inflammatory rheumatic diseases-The 10-year update

Seminars in Arthritis and Rheumatism

Volumn 43, Issue 3, 2013, Pages 392-404

  Straub, Rainer H ^a   Bijlsma, Johannes W J ^b   Masi, Alfonse ^c   Cutolo, Maurizio ^d  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF ILLINOIS   (United States)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

Hormones; Nervous system; Neuroendocrine immunology; Neurotransmitters; Rheumatic diseases

Indexed keywords

ALPHA INTERMEDIN; ANDROGEN; ANTALARMIN; APREMILAST; BROMOCRIPTINE; BUNGAROTOXIN RECEPTOR; CORTICOTROPIN; ESTROGEN; FOLLITROPIN; GLUCOCORTICOID; HYDROCORTISONE; INTERLEUKIN 17; LUTEINIZING HORMONE; MELATONIN; PHOSPHODIESTERASE IV INHIBITOR; PRASTERONE; PRASTERONE SULFATE; PREDNISONE; PROLACTIN; VASOACTIVE INTESTINAL POLYPEPTIDE;

ADRENERGIC SYSTEM; ANKYLOSING SPONDYLITIS; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CHOLINERGIC SYSTEM; CHRONIC INFLAMMATION; CIRCADIAN RHYTHM; CORTICOTROPIN RELEASE; HUMAN; HYDROCORTISONE RELEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS THYROID SYSTEM; IMMUNOMODULATION; LOW DRUG DOSE; MACROPHAGE; MORNING DOSAGE; NEUROENDOCRINE SYSTEM; NEUROIMMUNOLOGY; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REGULATORY T LYMPHOCYTE; RHEUMATIC DISEASE; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; SJOEGREN SYNDROME; STEROIDOGENESIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TH17 CELL;

HORMONES; NERVOUS SYSTEM; NEUROENDOCRINE IMMUNOLOGY; NEUROTRANSMITTERS; RHEUMATIC DISEASES;

CHRONIC DISEASE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INFLAMMATION; NEUROIMMUNOMODULATION; PITUITARY-ADRENAL SYSTEM; RHEUMATIC DISEASES;

EID: 84889609799     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2013.04.008     Document Type: Article

References (197)

1. Straub R.H., Cutolo M. Involvement of the hypothalamic-pituitary-adrenal/gonadal axis and the peripheral nervous system in rheumatoid arthritis: viewpoint based on a systemic pathogenetic role. Arthritis Rheum 2001, 44:493-507.
2. Schmidt-Wilcke T., Clauw D.J. Fibromyalgia: from pathophysiology to therapy. Nat Rev Rheumatol 2011, 7:518-527.
3. Evers A.W., Zautra A., Thieme K. Stress and resilience in rheumatic diseases: a review and glimpse into the future. Nat Rev Rheumatol 2011, 7:409-415.
4. Hench P.S. The ameliorating effect of pregnancy on chronic atrophic (infectious, rheumatoid) arthritis, fibrositis, and intermittent hydrarthrosis. Proc Staff Meetings Mayo Clinic 1938, 13:161-167.
5. Straub R.H. The complex role of estrogens in inflammation. Endocr Rev 2007, 28:521-574.
6. Carlsten H., Nilsson N., Jonsson R., Backman K., Holmdahl R., Tarkowski A. Estrogen accelerates immune complex glomerulonephritis but ameliorates T cell-mediated vasculitis and sialadenitis in autoimmune MRL lpr/lpr mice 86. Cell Immunol 1992, 144:190-202.
7. Cutolo M., Capellino S., Montagna P., Villaggio B., Sulli A., Seriolo B., et al. New roles for estrogens in rheumatoid arthritis. Clin Exp Rheumatol 2003, 21:687-690.
8. Ganesan K., Balachandran C., Manohar B.M., Puvanakrishnan R. Effects of testosterone, estrogen and progesterone on TNF-alpha mediated cellular damage in rat arthritic synovial fibroblasts. Rheumatol Int 2012, 32:3181-3188.
9. Masi A.T., Chrousos G.P., Bornstein S.R. Enigmas of adrenal androgen and glucocorticoid dissociation in premenopausal onset rheumatoid arthritis. J Rheumatol 1999, 26:247-250.
10. Hanna F.S., Bell R.J., Cicuttini F.M., Davison S.L., Wluka A.E., Davis S.R. The relationship between endogenous testosterone, preandrogens, and sex hormone binding globulin and knee joint structure in women at midlife. Semin Arthritis Rheum 2007, 37:56-62.
11. Straub R.H., Paimela L., Peltomaa R., Schölmerich J., Leirisalo-Repo M. Inadequately low serum levels of steroid hormones in relation to IL-6 and TNF in untreated patients with early rheumatoid arthritis and reactive arthritis. Arthritis Rheum 2002, 46:654-662.
12. Stark K., Schmidt M., Rovensky J., Blazickova S., Lowin T., Straub R.H. Influence of CYB5A gene variants on risk of rheumatoid arthritis and local endocrine function in the joint. Brain Behav Immun 2013, 29(Suppl):S12-S13.
13. Castagnetta L.A., Carruba G., Granata O.M., Stefano R., Miele M., Schmidt M., et al. Increased estrogen formation and estrogen to androgen ratio in the synovial fluid of patients with rheumatoid arthritis. J Rheumatol 2003, 30:2597-2605.
14. Schmidt M., Weidler C., Naumann H., Schölmerich J., Straub R.H. Androgen conversion in osteoarthritis and rheumatoid arthritis synoviocytes-androstenedione and testosterone inhibit estrogen formation and favor production of more potent 5alpha-reduced androgens. Arthritis Res Ther 2005, 7:R938-48.
15. Herrmann M., Schölmerich J., Straub R.H. Influence of cytokines and growth factors on distinct steroidogenic enzymes in vitro: a short tabular data collection. Ann N Y Acad Sci 2002, 966:166-186.
16. Weidler C., Struharova S., Schmidt M., Ugele B., Schölmerich J., Straub R.H. Tumor necrosis factor inhibits conversion of dehydroepiandrosterone sulfate (DHEAS) to DHEA in rheumatoid arthritis synovial cells: a prerequisite for local androgen deficiency. Arthritis Rheum 2005, 52:1721-1729.
17. Dulos J., Verbraak E., Bagchus W.M., Boots A.M., Kaptein A. Severity of murine collagen-induced arthritis correlates with increased CYP7B activity: enhancement of dehydroepiandrosterone metabolism by interleukin-1beta. Arthritis Rheum 2004, 50:3346-3353.
18. Schmidt M., Hartung R., Capellino S., Cutolo M., Pfeifer-Leeg A., Straub R.H. Estrone/17beta-estradiol conversion to, and tumor necrosis factor inhibition by, estrogen metabolites in synovial cells of patients with rheumatoid arthritis and patients with osteoarthritis. Arthritis Rheum 2009, 60:2913-2922.
19. Cutolo M., Capellino S., Straub R.H. Oestrogens in rheumatic diseases: friend or foe?. Rheumatology (Oxford) 2008, 47(Suppl 3):iii2-iii5.
20. Rivier C., Vale W. In the rat, interleukin-1 alpha acts at the level of the brain and the gonads to interfere with gonadotropin and sex steroid secretion. Endocrinology 1989, 124:2105-2109.
21. Gordon D., Beastall G.H., Thomson J.A., Sturrock R.D. Androgenic status and sexual function in males with rheumatoid arthritis and ankylosing spondylitis. Q J Med 1986, 60:671-679.
22. El M.A., Tellal S., Chaouir S., Lebbar K., Bezza A., Nouijai A., et al. Bone turnover markers, anterior pituitary and gonadal hormones, and bone mass evaluation using quantitative computed tomography in ankylosing spondylitis. Clin Rheumatol 2005, 24:346-351.
23. Suehiro R.M., Borba E.F., Bonfa E., Okay T.S., Cocuzza M., Soares P.M., et al. Testicular sertoli cell function in male systemic lupus erythematosus. Rheumatology (Oxford) 2008, 47:1692-1697.
24. Johnson E.O., Moutsopoulos H.M. Neuroendocrine manifestations in Sjogren's syndrome. Relation to the neurobiology of stress. Ann N Y Acad Sci 2000, 917:797-808.
25. Tengstrand B., Carlstrom K., Hafstrom I. Bioavailable testosterone in men with rheumatoid arthritis-high frequency of hypogonadism. Rheumatology (Oxford) 2002, 41:285-289.
26. Silva C.A., Deen M.E., Febronio M.V., Oliveira S.K., Terreri M.T., Sacchetti S.B., et al. Hormone profile in juvenile systemic lupus erythematosus with previous or current amenorrhea. Rheumatol Int 2011, 31:1037-1043.
27. Koller M.D., Templ E., Riedl M., Clodi M., Wagner O., Smolen J.S., et al. Pituitary function in patients with newly diagnosed untreated systemic lupus erythematosus. Ann Rheum Dis 2004, 63:1677-1680.
28. Soares P.M., Borba E.F., Bonfa E., Hallak J., Correa A.L., Silva C.A. Gonad evaluation in male systemic lupus erythematosus. Arthritis Rheum 2007, 56:2352-2361.
29. Villiger P.M., Caliezi G., Cottin V., Forger F., Senn A., Ostensen M. Effects of TNF antagonists on sperm characteristics in patients with spondyloarthritis. Ann Rheum Dis 2010, 69:1842-1844.
30. Masi A.T., Aldag J.C., Chatterton R.T. Neuroendocrine immune perturbations in rheumatoid arthritis: causes, consequences, or confounders in the disease process?. J Rheumatol 2003, 30:2302-2305.
31. Heikkila R., Aho K., Heliovaara M., Knekt P., Reunanen A., Aromaa A., et al. Serum androgen-anabolic hormones and the risk of rheumatoid arthritis. Ann Rheum Dis 1998, 57:281-285.
32. Karlson E.W., Chibnik L.B., McGrath M., Chang S.C., Keenan B.T., Costenbader K.H., et al. A prospective study of androgen levels, hormone-related genes and risk of rheumatoid arthritis. Arthritis Res Ther 2009, 11:R97.
33. Sternberg E.M., Hill J.M., Chrousos G.P., Kamilaris T., Listwak S.J., Gold P.W., et al. Inflammatory mediator-induced hypothalamic-pituitary-adrenal axis activation is defective in streptococcal cell wall arthritis-susceptible Lewis rats. Proc Natl Acad Sci U S A 1989, 86:2374-2378.
34. Jessop D.S., Harbuz M.S. A defect in cortisol production in rheumatoid arthritis: why are we still looking?. Rheumatology (Oxford) 2005, 44:1097-1100.
35. Dekkers J.C., Geenen R., Godaert G.L., Glaudemans K.A., Lafeber F.P., van Doornen L.J., et al. Experimentally challenged reactivity of the hypothalamic pituitary adrenal axis in patients with recently diagnosed rheumatoid arthritis. J Rheumatol 2001, 28:1496-1504.
36. Pool A.J., Whipp B.J., Skasick A.J., Alavi A., Bland J.M., Axford J.S. Serum cortisol reduction and abnormal prolactin and CD4+/CD8+ T-cell response as a result of controlled exercise in patients with rheumatoid arthritis and systemic lupus erythematosus despite unaltered muscle energetics. Rheumatology (Oxford) 2004, 43:43-48.
37. Tsigos C., Papanicolaou D.A., Defensor R., Mitsiadis C.S., Kyrou I., Chrousos G.P. Dose effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure. Neuroendocrinology 1997, 66:54-62.
38. Jablons D.M., Mule J.J., McIntosh J.K., Sehgal P.B., May L.T., Huang C.M., et al. IL-6/IFN-beta-2 as a circulating hormone. Induction by cytokine administration in humans. J Immunol 1989, 142:1542-1547.
39. Straub R., Buttgereit F., Cutolo M. Alterations of the hypothalamic-pituitary-adrenal axis in systemic immune diseases-a role for misguided energy regulation. Clin Exp Rheumatol 2011, 29(Suppl. 68):S15-S23.
40. Straub R.H., Cutolo M. Further evidence for insufficient hypothalamic-pituitary-glandular axes in polymyalgia rheumatica. J Rheumatol 2006, 33:1219-1223.
41. Straub R.H., Pongratz G., Schölmerich J., Kees F., Schaible T.F., Antoni C., et al. Long-term anti-tumor necrosis factor antibody therapy in rheumatoid arthritis patients sensitizes the pituitary gland and favors adrenal androgen secretion. Arthritis Rheum 2003, 48:1504-1512.
42. Straub R.H., Harle P., Yamana S., Matsuda T., Takasugi K., Kishimoto T., et al. Anti-interleukin-6 receptor antibody therapy favors adrenal androgen secretion in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2006, 54:1778-1785.
43. Ernestam S., Hafstrom I., Werner S., Carlstrom K., Tengstrand B. Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function. J Rheumatol 2007, 34:1451-1458.
44. Tengstrand B., Carlstrom K., Hafstrom I. Gonadal hormones in men with rheumatoid arthritis-from onset through 2 years. J Rheumatol 2009, 36:887-892.
45. Straub R.H., Pongratz G., Cutolo M., Wijbrandts C.A., Baeten D., Fleck M., et al. Increased cortisol relative to adrenocorticotropic hormone predicts improvement during anti-tumor necrosis factor therapy in rheumatoid arthritis. Arthritis Rheum 2008, 58:976-984.
46. Crofford L.J., Sano H., Karalis K., Friedman T.C., Epps H.R., Remmers E.F., et al. Corticotropin-releasing hormone in synovial fluids and tissues of patients with rheumatoid arthritis and osteoarthritis. J Immunol 1993, 151:1587-1596.
47. Murphy E.P., McEvoy A., Conneely O.M., Bresnihan B., Fitzgerald O. Involvement of the nuclear orphan receptor NURR1 in the regulation of corticotropin-releasing hormone expression and actions in human inflammatory arthritis. Arthritis Rheum 2001, 44:782-793.
48. Webster E.L., Barrientos R.M., Contoreggi C., Isaac M.G., Ligier S., Gabry K.E., et al. Corticotropin releasing hormone (CRH) antagonist attenuates adjuvant induced arthritis: role of CRH in peripheral inflammation. J Rheumatol 2002, 29:1252-1261.
49. Brzoska T., Luger T.A., Maaser C., Abels C., Böhm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev 2008, 29:581-602.
50. Ceriani G., Diaz J., Murphree S., Catania A., Lipton J.M. The neuropeptide alpha-melanocyte-stimulating hormone inhibits experimental arthritis in rats. Neuroimmunomodulation 1994, 1:28-32.
51. Walker S.E., Jacobson J.D. Roles of prolactin and gonadotropin-releasing hormone in rheumatic diseases. Rheum Dis Clin North Am 2000, 26:713-736.
52. Jara L.J., Medina G., Saavedra M.A., Vera-Lastra O., Navarro C. Prolactin and autoimmunity. Clin Rev Allergy Immunol 2011, 40:50-59.
53. Lee Y.C., Raychaudhuri S., Cui J., De V.I., Ding B., Alfredsson L., et al. The PRL-1149G/T polymorphism and rheumatoid arthritis susceptibility. Arthritis Rheum 2009, 60:1250-1254.
54. Matera L., Mori M., Geuna M., Buttiglieri S., Palestro G. Prolactin in autoimmunity and antitumor defence. J Neuroimmunol 2000, 109:47-55.
55. Cutolo M., Maestroni G.J. The melatonin-cytokine connection in rheumatoid arthritis. Ann Rheum Dis 2005, 64:1109-1111.
56. Forrest C.M., Mackay G.M., Stoy N., Stone T.W., Darlington L.G. Inflammatory status and kynurenine metabolism in rheumatoid arthritis treated with melatonin. Br J Clin Pharmacol 2007, 64:517-526.
57. Cutolo M., Straub R.H., Buttgereit F. Circadian rhythms of nocturnal hormones in rheumatoid arthritis: translation from bench to bedside. Ann Rheum Dis 2008, 67:905-908.
58. Srinivasan V., Spence D.W., Trakht I., Pandi-Perumal S.R., Cardinali D.P., Maestroni G.J. Immunomodulation by melatonin: its significance for seasonally occurring diseases. Neuroimmunomodulation 2008, 15:93-101.
59. Huang S.A., Bianco A.C. Reawakened interest in type III iodothyronine deiodinase in critical illness and injury. Nat Clin Pract Endocrinol Metab 2008, 4:148-155.
60. Kumar K., Kole A.K., Karmakar P.S., Ghosh A. The spectrum of thyroid disorders in systemic lupus erythematosus. Rheumatol Int 2012, 32:73-78.
61. Raterman H.G., Jamnitski A., Lems W.F., Voskuyl A.E., Dijkmans B.A., Bos W.H., et al. Improvement of thyroid function in hypothyroid patients with rheumatoid arthritis after 6 months of adalimumab treatment: a pilot study. J Rheumatol 2011, 38:247-251.
62. Straub R.H., Cutolo M. Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management. Arthritis Rheum 2007, 56:399-408.
63. Clarke L., Jessop D., Hunt L., Straub R., Perry M., Kirwan J. Alleviation of morning joint stiffness by low-dose prednisone in rheumatoid arthritis is associated with circadian changes in IL-6 and cortisol. Int J Clin Rheumatol 2011, 6:241-249.
64. Crofford L.J., Kalogeras K.T., Mastorakos G., Magiakou M.A., Wells J., Kanik K.S., et al. Circadian relationships between interleukin (IL)-6 and hypothalamic-pituitary-adrenal axis hormones: failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis. J Clin Endocrinol Metab 1997, 82:1279-1283.
65. Meyer-Hermann M., Figge M.T., Straub R.H. Mathematical modeling of the circadian rhythm of key neuroendocrine-immune system players in rheumatoid arthritis: a systems biology approach. Arthritis Rheum 2009, 60:2585-2594.
66. Buttgereit F., Doering G., Schaeffler A., Witte S., Sierakowski S., Gromnica-Ihle E., et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet 2008, 371:205-214.
67. Pongratz G., Straub R.H. Role of peripheral nerve fibres in acute and chronic inflammation in arthritis. Nat Rev Rheumatol 2013, 9:117-126.
68. Härle P., Mobius D., Carr D.J., Schölmerich J., Straub R.H. An opposing time-dependent immune-modulating effect of the sympathetic nervous system conferred by altering the cytokine profile in the local lymph nodes and spleen of mice with type II collagen-induced arthritis. Arthritis Rheum 2005, 52:1305-1313.
69. Ebbinghaus M., Gajda M., Boettger M.K., Schaible H.G., Brauer R. The anti-inflammatory effects of sympathectomy in murine antigen-induced arthritis are associated with a reduction of Th1 and Th17 responses. Ann Rheum Dis 2012, 71:253-261.
70. Lorton D., Lubahn C., Lindquist C.A., Schaller J., Washington C., Bellinger D.L. Changes in the density and distribution of sympathetic nerves in spleens from Lewis rats with adjuvant-induced arthritis suggest that an injury and sprouting response occurs. J Comp Neurol 2005, 489:260-273.
71. Straub R.H., Rauch L., Fassold A., Lowin T., Pongratz G. Neuronally released sympathetic neurotransmitters stimulate splenic interferon-gamma secretion from T cells in early type II collagen-induced arthritis. Arthritis Rheum 2008, 58:3450-3460.
72. Del Rey A., Wolff C., Wildmann J., Randolf A., Hahnel A., Besedovsky H.O., et al. Disrupted joint-immune-brain communication during experimental arthritis. Arthritis Rheum 2008, 58:3090-3099.
73. Mei Q., Mundinger T.O., Lernmark A., Taborsky Jr. Early, selective, and marked loss of sympathetic nerves from the islets of BioBreeder diabetic rats. Diabetes 2002, 51:2997-3002.
74. Miller L.E., Weidler C., Falk W., Angele P., Schaumburger J., Schölmerich J., et al. Increased prevalence of semaphorin 3C, a repellent of sympathetic nerve fibers, in the synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum 2004, 50:1156-1163.
75. Fassold A., Falk W., Anders S., Hirsch T., Mirsky V.M., Straub R.H. Soluble neuropilin-2, a nerve repellent receptor, is increased in rheumatoid arthritis synovium and aggravates sympathetic fiber repulsion and arthritis. Arthritis Rheum 2009, 60:2892-2901.
76. Straub R.H., Grum F., Strauch U.G., Capellino S., Bataille F., Bleich A., et al. Anti-inflammatory role of sympathetic nerves in chronic intestinal inflammation. Gut 2008, 57:911-921.
77. Miller L.E., Jüsten H.P., Schölmerich J., Straub R.H. The loss of sympathetic nerve fibers in the synovial tissue of patients with rheumatoid arthritis is accompanied by increased norepinephrine release from synovial macrophages. FASEB J 2000, 14:2097-2107.
78. Capellino S., Cosentino M., Wolff C., Schmidt M., Grifka J., Straub R.H. Catecholamine-producing cells in the synovial tissue during arthritis: modulation of sympathetic neurotransmitters as new therapeutic target. Ann Rheum Dis 2010, 69:1853-1860.
79. Capellino S., Weber K., Gelder M., Harle P., Straub R.H. First appearance and location of catecholaminergic cells during experimental arthritis and elimination by chemical sympathectomy. Arthritis Rheum 2012, 64:1110-1118.
80. Dekkers J.C., Geenen R., Godaert G.L., Bijlsma J.W., van Doornen L.J. Elevated sympathetic nervous system activity in patients with recently diagnosed rheumatoid arthritis with active disease. Clin Exp Rheumatol 2004, 22:63-70.
81. Härle P., Straub R.H., Wiest R., Maier A., Schölmerich J., Atzeni F., et al. Increase of sympathetic outflow measured by NPY and decrease of the hypothalamic-pituitary-adrenal axis tone in patients with SLE and RA-Another example of uncoupling of response systems. Ann Rheum Dis 2005, 65:51-56.
82. Straub R.H., Herfarth H., Falk W., Andus T., Schölmerich J. Uncoupling of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis in inflammatory bowel disease?. J Neuroimmunol 2002, 126:116-125.
83. Imrich R., Rovensky J., Malis F., Zlnay M., Killinger Z., Kvetnansky R., et al. Low levels of dehydroepiandrosterone sulphate in plasma, and reduced sympathoadrenal response to hypoglycaemia in premenopausal women with rheumatoid arthritis. Ann Rheum Dis 2005, 64:202-206.
84. Goldstein R.S., Bruchfeld A., Yang L., Qureshi A.R., Gallowitsch-Puerta M., Patel N.B., et al. Cholinergic anti-inflammatory pathway activity and High Mobility Group Box-1 (HMGB1) serum levels in patients with rheumatoid arthritis. Mol Med 2007, 13:210-215.
85. Tracey K.J. Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest 2007, 117:289-296.
86. Wahle M., Hanefeld G., Brunn S., Straub R.H., Wagner U., Krause A., et al. Failure of catecholamines to shift T-cell cytokine responses toward a Th2 profile in patients with rheumatoid arthritis. Arthritis Res Ther 2006, 8:R138.
87. Heijnen C.J., Roupe van der Voort C., Wulffraat N., van der N.J., Kuis W., Kavelaars A. Functional alpha 1-adrenergic receptors on leukocytes of patients with polyarticular juvenile rheumatoid arthritis. J Neuroimmunol 1996, 71:223-226.
88. Lombardi M.S., Kavelaars A., Cobelens P.M., Schmidt R.E., Schedlowski M., Heijnen C.J. Adjuvant arthritis induces down-regulation of G protein-coupled receptor kinases in the immune system. J Immunol 2001, 166:1635-1640.
89. Gonzalez-Rey E., Anderson P., Delgado M. Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy. Ann Rheum Dis 2007, 66(Suppl. 3):iii70-iii76.
90. Borovikova L.V., Ivanova S., Zhang M., Yang H., Botchkina G.I., Watkins L.R., et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000, 405:458-462.
91. Wang H., Yu M., Ochani M., Amella C.A., Tanovic M., Susarla S., et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003, 421:384-388.
92. Waldburger J.M., Boyle D.L., Pavlov V.A., Tracey K.J., Firestein G.S. Acetylcholine regulation of synoviocyte cytokine expression by the alpha7 nicotinic receptor. Arthritis Rheum 2008, 58:3439-3449.
93. van Maanen M.A., Lebre M.C., van der P.T., Larosa G.J., Elbaum D., Vervoordeldonk M.J., et al. Stimulation of nicotinic acetylcholine receptors attenuates collagen-induced arthritis in mice. Arthritis Rheum 2009, 60:114-122.
94. Konttinen Y.T., Kemppinen P., Segerberg M., Hukkanen M., Rees R., Santavirta S., et al. Peripheral and spinal neural mechanisms in arthritis, with particular reference to treatment of inflammation and pain. Arthritis Rheum 1994, 37:965-982.
95. Milligan E.D., Watkins L.R. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci 2009, 10:23-36.
96. Boyle D.L., Jones T.L., Hammaker D., Svensson C.I., Rosengren S., Albani S., et al. Regulation of peripheral inflammation by spinal p38 MAP kinase in rats. PLoS Med 2006, 3:e338.
97. Boettger M.K., Weber K., Grossmann D., Gajda M., Bauer R., Bar K.J., et al. Spinal tumor necrosis factor alpha neutralization reduces peripheral inflammation and hyperalgesia and suppresses autonomic responses in experimental arthritis: a role for spinal tumor necrosis factor alpha during induction and maintenance of peripheral inflammation. Arthritis Rheum 2010, 62:1308-1318.
98. de Mos M., Laferriere A., Millecamps M., Pilkington M., Sturkenboom M.C., Huygen F.J., et al. Role of NFkappaB in an animal model of complex regional pain syndrome-type I (CRPS-I). J Pain 2009, 10:1161-1169.
99. Sluka K.A., Rees H., Chen P.S., Tsuruoka M., Willis W.D. Inhibitors of G-proteins and protein kinases reduce the sensitization to mechanical stimulation and the desensitization to heat of spinothalamic tract neurons induced by intradermal injection of capsaicin in the primate. Exp Brain Res 1997, 115:15-24.
100. Lin Q., Peng Y.B., Willis W.D. Possible role of protein kinase C in the sensitization of primate spinothalamic tract neurons. J Neurosci 1996, 16:3026-3034.
101. Gao Y.J., Ji R.R. Targeting astrocyte signaling for chronic pain. Neurotherapeutics 2010, 7:482-493.
102. Dominguez E., Mauborgne A., Mallet J., Desclaux M., Pohl M. SOCS3-mediated blockade of JAK/STAT3 signaling pathway reveals its major contribution to spinal cord neuroinflammation and mechanical allodynia after peripheral nerve injury. J Neurosci 2010, 30:5754-5766.
103. Inoue K., Tsuda M., Koizumi S. ATP- and adenosine-mediated signaling in the central nervous system: chronic pain and microglia: involvement of the ATP receptor P2×4. J Pharmacol Sci 2004, 94:112-114.
104. Sorkin L.S., Boyle D.L., Hammaker D., Herman D.S., Vail E., Firestein G.S. MKK3 an upstream activator of p38, contributes to formalin phase 2 and late allodynia in mice. Neuroscience 2009, 162:462-471.
105. Katsura H., Obata K., Mizushima T., Sakurai J., Kobayashi K., Yamanaka H., et al. Activation of Src-family kinases in spinal microglia contributes to mechanical hypersensitivity after nerve injury. J Neurosci 2006, 26:8680-8690.
106. Vanegas H., Schaible H.G. Prostaglandins and cyclooxygenases [correction of cycloxygenases] in the spinal cord. Prog Neurobiol 2001, 64:327-363.
107. Christianson C.A., Corr M., Firestein G.S., Mobargha A., Yaksh T.L., Svensson C.I. Characterization of the acute and persistent pain state present in K/BxN serum transfer arthritis. Pain 2010, 151:394-403.
108. Brenn D., Richter F., Schaible H.G. Sensitization of unmyelinated sensory fibers of the joint nerve to mechanical stimuli by interleukin-6 in the rat: an inflammatory mechanism of joint pain. Arthritis Rheum 2007, 56:351-359.
109. Straub R.H., Linde H.J., Männel D.N., Schölmerich J., Falk W. A bacteria-induced switch of sympathetic effector mechanisms augments local inhibition of TNF-alpha and IL-6 secretion in the spleen. FASEB J 2000, 14:1380-1388.
110. Straub R.H., Besedovsky H.O. Integrated evolutionary, immunological, and neuroendocrine framework for the pathogenesis of chronic disabling inflammatory diseases. FASEB J 2003, 17:2176-2183.
111. Straub R.H., Cutolo M., Buttgereit F., Pongratz G. Energy regulation and neuroendocrine-immune control in chronic inflammatory diseases. J Intern Med 2010, 267:543-560.
112. Straub R.H. Concepts of evolutionary medicine and energy regulation contribute to the etiology of systemic chronic inflammatory diseases. Brain Behav Immun 2011, 25:1-5.
113. Straub R.H. Evolutionary medicine and chronic inflammatory state-known and new concepts in pathophysiology. J Mol Med 2012, 90:523-534.
114. Kirkwood T.B., Austad S.N. Why do we age?. Nature 2000, 408:233-238.
115. Dantzer R., Kelley K.W. Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun 2007, 21:153-160.
116. Petri M.A., Mease P.J., Merrill J.T., Lahita R.G., Iannini M.J., Yocum D.E., et al. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum 2004, 50:2858-2868.
117. Chang D.M., Lan J.L., Lin H.Y., Luo S.F. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46:2924-2927.
118. Forsblad-d'Elia H., Carlsten H., Labrie F., Konttinen Y.T., Ohlsson C. Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations. J Clin Endocrinol Metab 2009, 94:2044-2051.
119. Giltay E.J., van Schaardenburg D., Gooren L.J., von Blomberg B.M., Fonk J.C., Touw D.J., et al. Effects of dehydroepiandrosterone administration on disease activity in patients with rheumatoid arthritis. Br J Rheumatol 1998, 37:705-706.
120. Hartkamp A., Geenen R., Godaert G.L., Bootsma H., Kruize A.A., Bijlsma J.W., et al. Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sjogren syndrome: a randomised controlled trial. Ann Rheum Dis 2008, 67:91-97.
121. Hartkamp A., Geenen R., Godaert G.L., Bijl M., Bijlsma J.W., Derksen R.H. Effects of dehydroepiandrosterone on fatigue and well-being in women with quiescent systemic lupus erythematosus: a randomised controlled trial. Ann Rheum Dis 2010, 69:1144-1147.
122. Kirwan J.R., Bijlsma J.W., Boers M., Shea B.J. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007, 24. CD006356.
123. Jacobs J.W., van Everdingen A.A., Verstappen S.M., Bijlsma J.W. Followup radiographic data on patients with rheumatoid arthritis who participated in a two-year trial of prednisone therapy or placebo. Arthritis Rheum 2006, 54:1422-1428.
124. Buttgereit F., Burmester G.R., Straub R.H., Seibel M.J., Zhou H. Exogenous and endogenous glucocorticoids in rheumatic diseases. Arthritis Rheum 2011, 63:1-9.
125. Man H.W., Schafer P., Wong L.M., Patterson R.T., Corral L.G., Raymon H., et al. Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihy dro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor. J Med Chem 2009, 52:1522-1524.
126. McCann F.E., Palfreeman A.C., Andrews M., Perocheau D.P., Inglis J.J., Schafer P., et al. Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. Arthritis Res Ther 2010, 12:R107.
127. Schett G., Wollenhaupt J., Papp K., Joos R., Rodrigues J.F., Vessey A.R., et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2012, 64:3156-3167.
128. Elenkov I.J., Chrousos G.P. Stress hormones, proinflammatory and antiinflammatory cytokines, and autoimmunity. Ann N Y Acad Sci 2002, 966:290-303.
129. Lubahn C.L., Schaller J.A., Bellinger D.L., Sweeney S., Lorton D. The importance of timing of adrenergic drug delivery in relation to the induction and onset of adjuvant-induced arthritis. Brain Behav Immun 2004, 18:563-571.
130. Deng J., Liu Y., Yang M., Wang S., Zhang M., Wang X., et al. Leptin exacerbates collagen-induced arthritis via enhancement of Th17 cell response. Arthritis Rheum 2012, 64:3564-3573.
131. Mikami N., Watanabe K., Hashimoto N., Miyagi Y., Sueda K., Fukada S., et al. Calcitonin gene-related peptide enhances experimental autoimmune encephalomyelitis by promoting Th17-cell functions. Int Immunol 2012, 24:681-691.
132. Yadav M., Rosenbaum J., Goetzl E.J. Cutting edge: vasoactive intestinal peptide (VIP) induces differentiation of Th17 cells with a distinctive cytokine profile. J Immunol 2008, 180:2772-2776.
133. Ding W., Manni M., Stohl L.L., Zhou X.K., Wagner J.A., Granstein R.D. Pituitary adenylate cyclase-activating peptide and vasoactive intestinal polypeptide bias Langerhans cell Ag presentation toward Th17 cells. Eur J Immunol 2012, 42:901-911.
134. Cunin P., Caillon A., Corvaisier M., Garo E., Scotet M., Blanchard S., et al. The tachykinins substance P and hemokinin-1 favor the generation of human memory Th17 cells by inducing IL-1beta, IL-23, and TNF-like 1A expression by monocytes. J Immunol 2011, 186:4175-4182.
135. Barros P.O., Ferreira T.B., Vieira M.M., Almeida C.R., raujo-Lima C.F., Silva-Filho R.G., et al. Substance P enhances Th17 phenotype in individuals with generalized anxiety disorder: an event resistant to glucocorticoid inhibition. J Clin Immunol 2011, 31:51-59.
136. Manni M., Granstein R.D., Maestroni G. Beta2-adrenergic agonists bias TLR-2 and NOD2 activated dendritic cells towards inducing an IL-17 immune response. Cytokine 2011, 55:380-386.
137. Prado C., Contreras F., Gonzalez H., Diaz P., Elgueta D., Barrientos M., et al. Stimulation of dopamine receptor D5 expressed on dendritic cells potentiates Th17-mediated immunity. J Immunol 2012, 188:3062-3070.
138. Nakano K., Yamaoka K., Hanami K., Saito K., Sasaguri Y., Yanagihara N., et al. Dopamine induces IL-6-dependent IL-17 production via D1-like receptor on CD4 naive T cells and D1-like receptor antagonist SCH-23390 inhibits cartilage destruction in a human rheumatoid arthritis/SCID mouse chimera model. J Immunol 2011, 186:3745-3752.
139. Kim B.J., Jones H.P. Epinephrine-primed murine bone marrow-derived dendritic cells facilitate production of IL-17A and IL-4 but not IFN-gamma by CD4+ T cells. Brain Behav Immun 2010, 24:1126-1136.
140. Herrada A.A., Contreras F.J., Marini N.P., Amador C.A., Gonzalez P.A., Cortes C.M., et al. Aldosterone promotes autoimmune damage by enhancing Th17-mediated immunity. J Immunol 2010, 184:191-202.
141. Stepien T., Lawnicka H., Komorowski J., Stepien H., Siejka A. Growth hormone-releasing hormone stimulates the secretion of interleukin 17 from human peripheral blood mononuclear cells in vitro. Neuro Endocrinol Lett 2010, 31:852-856.
142. Härle P., Pongratz G., Albrecht J., Tarner I.H., Straub R.H. An early sympathetic nervous system influence exacerbates collagen-induced arthritis via CD4+CD25+ cells. Arthritis Rheum 2008, 58:2347-2355.
143. Liu M., Hu X., Wang Y., Peng F., Yang Y., Chen X., et al. Effect of high-dose methylprednisolone treatment on Th17 cells in patients with multiple sclerosis in relapse. Acta Neurol Scand 2009, 120:235-241.
144. Miljkovic Z., Momcilovic M., Miljkovic D., Mostarica-Stojkovic M. Methylprednisolone inhibits IFN-gamma and IL-17 expression and production by cells infiltrating central nervous system in experimental autoimmune encephalomyelitis. J Neuroinflammation 2009, 6:37.
145. Muls N., Jnaoui K., Dang H.A., Wauters A., Van S.J., Sindic C.J., et al. Upregulation of IL-17, but not of IL-9, in circulating cells of CIS and relapsing MS patients. Impact of corticosteroid therapy on the cytokine network. J Neuroimmunol 2012, 243:73-80.
146. Bosmann M., Meta F., Ruemmler R., Haggadone M.D., Sarma J.V., Zetoune F.S., et al. Regulation of IL-17 family members by adrenal hormones during experimental sepsis in mice. Am J Pathol 2013, 182:1124-1130.
147. Li N., Mu L., Wang J., Zhang J., Xie X., Kong Q., et al. Activation of the adenosine A2A receptor attenuates experimental autoimmune myasthenia gravis severity. Eur J Immunol 2012, 42:1140-1151.
148. Nakagome K., Imamura M., Okada H., Kawahata K., Inoue T., Hashimoto K., et al. Dopamine D1-like receptor antagonist attenuates Th17-mediated immune response and ovalbumin antigen-induced neutrophilic airway inflammation. J Immunol 2011, 186:5975-5982.
149. Nizri E., Irony-Tur-Sinai M., Lory O., Orr-Urtreger A., Lavi E., Brenner T. Activation of the cholinergic anti-inflammatory system by nicotine attenuates neuroinflammation via suppression of Th1 and Th17 responses. J Immunol 2009, 183:6681-6688.
150. Juarranz Y., Abad C., Martinez C., Arranz A., Gutierrez-Canas I., Rosignoli F., et al. Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res Ther 2005, 7:R1034-R1045.
151. Deng S., Xi Y., Wang H., Hao J., Niu X., Li W., et al. Regulatory effect of vasoactive intestinal peptide on the balance of Treg and Th17 in collagen-induced arthritis. Cell Immunol 2010, 265:105-110.
152. Wang C., Dehghani B., Li Y., Kaler L.J., Vandenbark A.A., Offner H. Oestrogen modulates experimental autoimmune encephalomyelitis and interleukin-17 production via programmed death 1. Immunology 2009, 126:329-335.
153. Relloso M., ragoneses-Fenoll L., Lasarte S., Bourgeois C., Romera G., Kuchler K., et al. Estradiol impairs the Th17 immune response against Candida albicans. J Leukoc Biol 2012, 91:159-165.
154. Lelu K., Laffont S., Delpy L., Paulet P.E., Perinat T., Tschanz S.A., et al. Estrogen receptor alpha signaling in T lymphocytes is required for estradiol-mediated inhibition of Th1 and Th17 cell differentiation and protection against experimental autoimmune encephalomyelitis. J Immunol 2011, 187:2386-2393.
155. Plum S.M., Park E.J., Strawn S.J., Moore E.G., Sidor C.F., Fogler W.E. Disease modifying and antiangiogenic activity of 2-methoxyestradiol in a murine model of rheumatoid arthritis. BMC Musculoskelet Disord 2009, 10:46.
156. Tyagi A.M., Srivastava K., Mansoori M.N., Trivedi R., Chattopadhyay N., Singh D. Estrogen deficiency induces the differentiation of IL-17 secreting Th17 cells: a new candidate in the pathogenesis of osteoporosis. PLoS One 2012, 7:e44552.
157. Yates M.A., Li Y., Chlebeck P., Proctor T., Vandenbark A.A., Offner H. Progesterone treatment reduces disease severity and increases IL-10 in experimental autoimmune encephalomyelitis. J Neuroimmunol 2010, 220:136-139.
158. Lee J.H., Ulrich B., Cho J., Park J., Kim C.H. Progesterone promotes differentiation of human cord blood fetal T cells into T regulatory cells but suppresses their differentiation into Th17 cells. J Immunol 2011, 187:1778-1787.
159. Li Q., Han D., Cong B., Shan B., Zhang J., Chen H., et al. Cholecystokinin octapeptide significantly suppresses collagen-induced arthritis in mice by inhibiting Th17 polarization primed by dendritic cells. Cell Immunol 2011, 272:53-60.
160. Tang J., Zhou R., Luger D., Zhu W., Silver P.B., Grajewski R.S., et al. Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the Th17 effector response. J Immunol 2009, 182:4624-4632.
161. Jeffery L.E., Burke F., Mura M., Zheng Y., Qureshi O.S., Hewison M., et al. 1,25-dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol 2009, 183:5458-5467.
162. Colin E.M., Asmawidjaja P.S., van Hamburg J.P., Mus A.M., van D.M., Hazes J.M., et al. 1,25-dihydroxyvitamin D3 modulates Th17 polarization and interleukin-22 expression by memory T cells from patients with early rheumatoid arthritis. Arthritis Rheum 2010, 62:132-142.
163. Chang S.H., Chung Y., Dong C. Vitamin D suppresses Th17 cytokine production by inducing C/EBP homologous protein (CHOP) expression. J Biol Chem 2010, 285:38751-38755.
164. Joshi S., Pantalena L.C., Liu X.K., Gaffen S.L., Liu H., Rohowsky-Kochan C., et al. 1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Mol Cell Biol 2011, 31:3653-3669.
165. van Hamburg J.P., Asmawidjaja P.S., Davelaar N., Mus A.M., Cornelissen F., van Leeuwen J.P., et al. TNF blockade requires 1,25(OH)2D3 to control human Th17-mediated synovial inflammation. Ann Rheum Dis 2012, 71:606-612.
166. Tian Y., Wang C., Ye Z., Xiao X., Kijlstra A., Yang P. Effect of 1,25-dihydroxyvitamin D3 on Th17 and Th1 response in patients with Behcet's disease. Invest Ophthalmol Vis Sci 2012, 53:6434-6441.
167. De R.V., Procaccini C., Cali G., Pirozzi G., Fontana S., Zappacosta S., et al. A key role of leptin in the control of regulatory T cell proliferation. Immunity 2007, 26:241-255.
168. Kipnis J., Cardon M., Avidan H., Lewitus G.M., Mordechay S., Rolls A., et al. Dopamine, through the extracellular signal-regulated kinase pathway, downregulates CD4+CD25+ regulatory T-cell activity: implications for neurodegeneration. J Neurosci 2004, 24:6133-6143.
169. Tiittanen M., Huupponen J.T., Knip M., Vaarala O. Insulin treatment in patients with type 1 diabetes induces upregulation of regulatory T-cell markers in peripheral blood mononuclear cells stimulated with insulin in vitro. Diabetes 2006, 55:3446-3454.
170. Taylor A.W., Lee D.J. The alpha-melanocyte stimulating hormone induces conversion of effector T cells into treg cells. J Transplant 2011, 246856.
171. Auriemma M., Brzoska T., Klenner L., Kupas V., Goerge T., Voskort M., et al. Alpha-MSH-stimulated tolerogenic dendritic cells induce functional regulatory T cells and ameliorate ongoing skin inflammation. J Invest Dermatol 2012, 132:1814-1824.
172. Polanczyk M.J., Carson B.D., Subramanian S., Afentoulis M., Vandenbark A.A., Ziegler S.F., et al. Cutting edge: estrogen drives expansion of the CD4+CD25+ regulatory T cell compartment. J Immunol 2004, 173:2227-2230.
173. Prieto G.A., Rosenstein Y. Oestradiol potentiates the suppressive function of human CD4 CD25 regulatory T cells by promoting their proliferation. Immunology 2006, 118:58-65.
174. Tai P., Wang J., Jin H., Song X., Yan J., Kang Y., et al. Induction of regulatory T cells by physiological level estrogen. J Cell Physiol 2008, 214:456-464.
175. Luo C.Y., Wang L., Sun C., Li D.J. Estrogen enhances the functions of CD4(+)CD25(+)Foxp3(+) regulatory T cells that suppress osteoclast differentiation and bone resorption in vitro. Cell Mol Immunol 2011, 8:50-58.
176. Mao G., Wang J., Kang Y., Tai P., Wen J., Zou Q., et al. Progesterone increases systemic and local uterine proportions of CD4+CD25+ Treg cells during midterm pregnancy in mice. Endocrinology 2010, 151:5477-5488.
177. Lee J.H., Lydon J.P., Kim C.H. Progesterone suppresses the mTOR pathway and promotes generation of induced regulatory T cells with increased stability. Eur J Immunol 2012, 42:2683-2696.
178. Fijak M., Schneider E., Klug J., Bhushan S., Hackstein H., Schuler G., et al. Testosterone replacement effectively inhibits the development of experimental autoimmune orchitis in rats: evidence for a direct role of testosterone on regulatory T cell expansion. J Immunol 2011, 186:5162-5172.
179. Fernandez-Martin A., Gonzalez-Rey E., Chorny A., Ganea D., Delgado M. Vasoactive intestinal peptide induces regulatory T cells during experimental autoimmune encephalomyelitis. Eur J Immunol 2006, 36:318-326.
180. Gonzalez-Rey E., Fernandez-Martin A., Chorny A., Delgado M. Vasoactive intestinal peptide induces CD4+,CD25+ T regulatory cells with therapeutic effect in collagen-induced arthritis. Arthritis Rheum 2006, 54:864-876.
181. Tan Y.V., Abad C., Lopez R., Dong H., Liu S., Lee A., et al. Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 2009, 106:2012-2017.
182. Wang D.W., Zhou R.B., Yao Y.M., Zhu X.M., Yin Y.M., Zhao G.J., et al. Stimulation of alpha7 nicotinic acetylcholine receptor by nicotine increases suppressive capacity of naturally occurring CD4+CD25+ regulatory T cells in mice in vitro. J Pharmacol Exp Ther 2010, 335:553-561.
183. Bhowmick S., Singh A., Flavell R.A., Clark R.B., O'Rourke J., Cone R.E. The sympathetic nervous system modulates CD4(+)FoxP3(+) regulatory T cells via a TGF-beta-dependent mechanism. J Leukoc Biol 2009, 86:1275-1283.
184. Chen X., Oppenheim J.J., Winkler-Pickett R.T., Ortaldo J.R., Howard O.M. Glucocorticoid amplifies IL-2-dependent expansion of functional FoxP3(+)CD4(+)CD25(+) T regulatory cells in vivo and enhances their capacity to suppress EAE. Eur J Immunol 2006, 36:2139-2149.
185. Ling Y., Cao X., Yu Z., Ruan C. Circulating dendritic cells subsets and CD4+Foxp3+ regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasome. Eur J Haematol 2007, 79:310-316.
186. Azab N.A., Bassyouni I.H., Emad Y., bd El-Wahab G.A., Hamdy G., Mashahit M.A. CD4+CD25+ regulatory T cells (TREG) in systemic lupus erythematosus (SLE) patients: the possible influence of treatment with corticosteroids. Clin Immunol 2008, 127:151-157.
187. Braitch M., Harikrishnan S., Robins R.A., Nichols C., Fahey A.J., Showe L., et al. Glucocorticoids increase CD4CD25 cell percentage and Foxp3 expression in patients with multiple sclerosis. Acta Neurol Scand 2009, 119:239-245.
188. Xie Y., Wu M., Song R., Ma J., Shi Y., Qin W., et al. A glucocorticoid amplifies IL-2-induced selective expansion of CD4(+)CD25(+)FOXP3(+) regulatory T cells in vivo and suppresses graft-versus-host disease after allogeneic lymphocyte transplantation. Acta Biochim Biophys Sin (Shanghai) 2009, 41:781-791.
189. Stary G., Klein I., Bauer W., Koszik F., Reininger B., Kohlhofer S., et al. Glucocorticosteroids modify Langerhans cells to produce TGF-beta and expand regulatory T cells. J Immunol 2011, 186:103-112.
190. Daniel C., Sartory N.A., Zahn N., Radeke H.H., Stein J.M. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J Pharmacol Exp Ther 2008, 324:23-33.
191. Baeke F., Korf H., Overbergh L., Verstuyf A., Thorrez L., Van L.L., et al. The vitamin D analog, TX527, promotes a human CD4+CD25highCD127low regulatory T cell profile and induces a migratory signature specific for homing to sites of inflammation. J Immunol 2011, 186:132-142.
192. van der Aar A.M., Sibiryak D.S., Bakdash G., van Capel T.M., van der Kleij H.P., Opstelten D.J., et al. Vitamin D3 targets epidermal and dermal dendritic cells for induction of distinct regulatory T cells. J Allergy Clin Immunol 2011, 127:1532-1540.
193. Kang S.W., Kim S.H., Lee N., Lee W.W., Hwang K.A., Shin M.S., et al. 1,25-dihyroxyvitamin D3 promotes FOXP3 expression via binding to vitamin D response elements in its conserved noncoding sequence region. J Immunol 2012, 188:5276-5282.
194. Esteban N.V., Loughlin T., Yergey A.L., Zawadzki J.K., Booth J.D., Winterer J.C., et al. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J Clin Endocrinol Metab 1991, 72:39-45.
195. Cooper M.S., Stewart P.M. Corticosteroid insufficiency in acutely ill patients. N Engl J Med 2003, 348:727-734.
196. Straub R.H., Lowin T., Klatt S., Wolff C., Rauch L. Increased density of sympathetic nerve fibers in metabolically activated fat tissue surrounding human synovium and mouse lymph nodes in arthritis. Arthritis Rheum 2011, 63:3234-3242.
197. Stein C., Schafer M., Machelska H. Attacking pain at its source: new perspectives on opioids. Nat Med 2003, 9:1003-1008.